Akari Therapeutics PLC (AKTX)
0.97
-0.03
(-2.99%)
USD |
NASDAQ |
Dec 20, 16:00
0.95
-0.02
(-2.06%)
After-Hours: 20:00
Akari Therapeutics Enterprise Value: 22.77M for Dec. 20, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 19.71M |
| Ascendis Pharma AS | 8.324B |
| Cellectis SA | -53.41M |
| Adaptimmune Therapeutics PLC | 18.53M |
| Biodexa Pharmaceuticals PLC | -3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.895M |
| Total Expenses (Quarterly) | 1.852M |
| EPS Diluted (Quarterly) | -0.2374 |
| Earnings Yield | -283.7% |